Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong international demand for weight-loss drugs ...

The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were ...

Eli Lilly said on Wednesday it will invest more than $1.2 billion to expand its manufacturing site in Puerto Rico, as the ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Patients will be able to access Eli Lilly's weight loss drug Zepbound at Walmart pharmacies nationwide through its ...